Session

IBD (Posters)

CANCER INCIDENCE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND A PRIOR NON-DIGESTIVE MALIGNANCY ACCORDING TO THE IMMUNOMODULATORY THERAPY: A MULTICENTER COHORT STUDY
CANCER INCIDENCE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND A PRIOR NON-DIGESTIVE MALIGNANCY ACCORDING TO THE IMMUNOMODULATORY THERAPY: A MULTICENTER COHORT STUDY

PRACTICAL DEEP LEARNING TOOL FOR SCORING OF ULCERATIVE COLITIS DISEASE ACTIVITY IN CENTRAL READING
PRACTICAL DEEP LEARNING TOOL FOR SCORING OF ULCERATIVE COLITIS DISEASE ACTIVITY IN CENTRAL READING

PERFUSE: A FRENCH NON-INTERVENTIONAL COHORT STUDY OF INFLIXIMAB-NAÏVE AND TRANSITIONED PATIENTS RECEIVING INFLIXIMAB BIOSIMILAR SB2; ANALYSIS OF 24-MONTH DATA
PERFUSE: A FRENCH NON-INTERVENTIONAL COHORT STUDY OF INFLIXIMAB-NAÏVE AND TRANSITIONED PATIENTS RECEIVING INFLIXIMAB BIOSIMILAR SB2; ANALYSIS OF 24-MONTH DATA

IMPACT OF BIOLOGICAL AGENTS ON POSTOPERATIVE COMPLICATIONS IN INFLAMMATORY BOWEL DISEASE: A MULTICENTRE STUDY OF GETECCU
IMPACT OF BIOLOGICAL AGENTS ON POSTOPERATIVE COMPLICATIONS IN INFLAMMATORY BOWEL DISEASE: A MULTICENTRE STUDY OF GETECCU

ETRASIMOD IMPROVES QUALITY OF LIFE IN ADULTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2 OASIS TRIAL AND OPEN-LABEL EXTENSION
ETRASIMOD IMPROVES QUALITY OF LIFE IN ADULTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2 OASIS TRIAL AND OPEN-LABEL EXTENSION

ADALIMUMAB 80MG EVERY OTHER WEEK IN INFLAMMATORY BOWEL DISEASE: TREATMENT INTENSIFICATION OUTCOMES IN REAL LIFE CLINICAL PRACTICE
ADALIMUMAB 80MG EVERY OTHER WEEK IN INFLAMMATORY BOWEL DISEASE: TREATMENT INTENSIFICATION OUTCOMES IN REAL LIFE CLINICAL PRACTICE

IMPACT OF OVERWEIGHT AND OBESITY ON DISEASE OUTCOME IN THE PEDIATRIC SWISS IBD COHORT
IMPACT OF OVERWEIGHT AND OBESITY ON DISEASE OUTCOME IN THE PEDIATRIC SWISS IBD COHORT

CONCOMITANT USE OF STATINS IN FILGOTINIB-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS
CONCOMITANT USE OF STATINS IN FILGOTINIB-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS

MISDIAGNOSIS IN PAEDIATRIC INFLAMMATORY BOWEL DISEASE - FINDINGS FROM A REAL-WORLD STUDY IN EUROPE
MISDIAGNOSIS IN PAEDIATRIC INFLAMMATORY BOWEL DISEASE - FINDINGS FROM A REAL-WORLD STUDY IN EUROPE

PATIENT-REPORTED OUTCOMES OF RESPONSE AND REMISSION FOLLOWING GUSELKUMAB INDUCTION TREATMENT AS MEASURED BY THE INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE: RESULTS THROUGH WEEK 12 OF THE PHASE 2 GALAXI 1 STUDY
PATIENT-REPORTED OUTCOMES OF RESPONSE AND REMISSION FOLLOWING GUSELKUMAB INDUCTION TREATMENT AS MEASURED BY THE INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE: RESULTS THROUGH WEEK 12 OF THE PHASE 2 GALAXI 1 STUDY

EARLY PRO-2 SYMPTOM REMISSION FOLLOWING GUSELKUMAB INDUCTION TREATMENT: RESULTS THROUGH WEEK 12 OF THE PHASE 2 GALAXI 1 STUDY
EARLY PRO-2 SYMPTOM REMISSION FOLLOWING GUSELKUMAB INDUCTION TREATMENT: RESULTS THROUGH WEEK 12 OF THE PHASE 2 GALAXI 1 STUDY

INFLAMMATORY BOWEL DISEASE NEW-ONSET DURING SECUKINUMAB THERAPY: REAL-WORLD DATA FROM A TERCIARY CENTRE
INFLAMMATORY BOWEL DISEASE NEW-ONSET DURING SECUKINUMAB THERAPY: REAL-WORLD DATA FROM A TERCIARY CENTRE

LONGITUDINAL DYNAMICS OF GUT MICROBIOME AND METABOLOME AFTER BIOLOGICAL THERAPY IN INFLAMMATORY BOWEL DISEASES
LONGITUDINAL DYNAMICS OF GUT MICROBIOME AND METABOLOME AFTER BIOLOGICAL THERAPY IN INFLAMMATORY BOWEL DISEASES

IMPORTANCE OF IBD BIOPSY PROTOCOL IN CLINICAL PRACTICE: ANALYSES COMPARING TWO BRITISH PATIENTS' COHORTS
IMPORTANCE OF IBD BIOPSY PROTOCOL IN CLINICAL PRACTICE: ANALYSES COMPARING TWO BRITISH PATIENTS' COHORTS

COMORBIDITIES AND EPIDEMIOLOGICAL RISK FACTOR BUT NOT IMMUNOSUPPRESSIVE THERAPIES INCREASE THE RISK OF COVID-19 IN INFLAMMATORY BOWEL DISEASE (IBD): AN ENEIDA-BASED, CASE-CONTROL STUDY
COMORBIDITIES AND EPIDEMIOLOGICAL RISK FACTOR BUT NOT IMMUNOSUPPRESSIVE THERAPIES INCREASE THE RISK OF COVID-19 IN INFLAMMATORY BOWEL DISEASE (IBD): AN ENEIDA-BASED, CASE-CONTROL STUDY

INFLAMMATORY BOWEL DISEASE (IBD) AND IMMUNOSUPPRESSION DO NOT WORSEN THE PROGNOSIS OF COVID-19. RESULTS FROM THE ENEIDA PROJECT OF GETECCU
INFLAMMATORY BOWEL DISEASE (IBD) AND IMMUNOSUPPRESSION DO NOT WORSEN THE PROGNOSIS OF COVID-19. RESULTS FROM THE ENEIDA PROJECT OF GETECCU

COMPARISON OF DAIRY FOODS INTOLERANCE BETWEEN INFLAMMATORY BOWEL DISEASE PATIENTS AND GENERAL POPULATION: A MULTINATIONAL CROSS SECTIONAL STUDY
COMPARISON OF DAIRY FOODS INTOLERANCE BETWEEN INFLAMMATORY BOWEL DISEASE PATIENTS AND GENERAL POPULATION: A MULTINATIONAL CROSS SECTIONAL STUDY

PREDICTORS OF CLINICAL RESPONSE AND INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE IMPROVEMENT WITH GOLIMUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ACTIVE ULCERATIVE COLITIS IN THE PURSUIT-MAINTENANCE STUDY
PREDICTORS OF CLINICAL RESPONSE AND INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE IMPROVEMENT WITH GOLIMUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ACTIVE ULCERATIVE COLITIS IN THE PURSUIT-MAINTENANCE STUDY

CLOSTRIDIUM DIFFICILE INFECTION IN PATIENTS TREATED WITH TOFACITINIB IN THE ULCERATIVE COLITIS CLINICAL PROGRAMME
CLOSTRIDIUM DIFFICILE INFECTION IN PATIENTS TREATED WITH TOFACITINIB IN THE ULCERATIVE COLITIS CLINICAL PROGRAMME

DEFINITION OF A MICROBIAL SIGNATURE AS A PREDICTOR OF POST-SURGICAL RECURRENCE IN PATIENTS WITH CROHN'S DISEASE
DEFINITION OF A MICROBIAL SIGNATURE AS A PREDICTOR OF POST-SURGICAL RECURRENCE IN PATIENTS WITH CROHN'S DISEASE

Item 241 - 260 / 568
1 2 3 4 5 6 7 8 9 10 11 12
13
14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29